Business Wire03.13.18
Tandem Diabetes Care Inc., manufacturer of the only touchscreen insulin pumps available in the United States, has entered into a distribution agreement with Rubin Medical to commercialize Tandem’s t:slim X2 Insulin Pump, insulin cartridges, and t:lock family of Infusion Sets in Sweden, Norway, and Denmark.
“This represents the first pump distribution agreement for Tandem Diabetes Care outside of the United States and is a significant step forward for our international commercialization strategy,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Rubin Medical’s success with insulin pumps in Sweden, Norway, and Denmark, and their demonstrated support of patients and clinicians impacted by diabetes, make them an ideal distributor for us in these countries.”
“We are thrilled to be able to bring the first touchscreen insulin pump to our diabetes communities in Scandinavia,” said Karl-Johan Öhman, CEO and managing director of Rubin Medical. “We believe the t:slim X2 Pump will be well received in these countries. We’re very happy to add this product to our portfolio and to be one of the first markets outside of the United States to offer this option to patients and clinics.”
Under the terms of the arrangement Rubin Medical will perform all sales, marketing and customer training and support for Tandem’s products. Timing for availability of Tandem products in Sweden, Norway, and Denmark has not been announced.
Tandem Diabetes Care Inc. designs, develops, and commercializes products for diabetics who use insulin. Tandem manufactures and sells the t:slim X2 Insulin Pump, the only pump capable of remote feature updates using a personal computer, now available with Dexcom G5 Mobile CGM integration, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, Calif.
Rubin Medical AB markets and sells diabetes products. The company is the exclusive distributor of the Animas insulin pump product in Sweden, Norway, and Denmark, where it has reached a strong market position. Rubin is a part of Indutrade AB, a company noted on the Swedish stock exchange.
“This represents the first pump distribution agreement for Tandem Diabetes Care outside of the United States and is a significant step forward for our international commercialization strategy,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Rubin Medical’s success with insulin pumps in Sweden, Norway, and Denmark, and their demonstrated support of patients and clinicians impacted by diabetes, make them an ideal distributor for us in these countries.”
“We are thrilled to be able to bring the first touchscreen insulin pump to our diabetes communities in Scandinavia,” said Karl-Johan Öhman, CEO and managing director of Rubin Medical. “We believe the t:slim X2 Pump will be well received in these countries. We’re very happy to add this product to our portfolio and to be one of the first markets outside of the United States to offer this option to patients and clinics.”
Under the terms of the arrangement Rubin Medical will perform all sales, marketing and customer training and support for Tandem’s products. Timing for availability of Tandem products in Sweden, Norway, and Denmark has not been announced.
Tandem Diabetes Care Inc. designs, develops, and commercializes products for diabetics who use insulin. Tandem manufactures and sells the t:slim X2 Insulin Pump, the only pump capable of remote feature updates using a personal computer, now available with Dexcom G5 Mobile CGM integration, and the t:flex Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, Calif.
Rubin Medical AB markets and sells diabetes products. The company is the exclusive distributor of the Animas insulin pump product in Sweden, Norway, and Denmark, where it has reached a strong market position. Rubin is a part of Indutrade AB, a company noted on the Swedish stock exchange.